Which medication is appropriate for a patient with sleep‑maintenance insomnia who did not benefit from melatonin and develops sleepwalking with diphenhydramine (Benadryl)?

Recommended Medication for Sleep-Maintenance Insomnia

For a patient with sleep-maintenance insomnia who failed melatonin and developed sleepwalking with diphenhydramine, prescribe a dual orexin receptor antagonist (DORA) such as daridorexant 25-50 mg nightly, or alternatively low-dose doxepin 3-6 mg nightly.

First-Line Pharmacologic Options

Dual Orexin Receptor Antagonists (DORAs)

DORAs are the optimal choice for sleep-maintenance insomnia in this clinical scenario 1. These medications work by blocking wakefulness signals rather than inducing sedation, which fundamentally differs from antihistamines like Benadryl and reduces the risk of parasomnias like sleepwalking.

Specific DORA recommendations:

• Daridorexant 25-50 mg: Most recent evidence shows superior efficacy for wake after sleep onset (WASO) with the best safety profile 2, 3, 4. It has an ideal 8-hour half-life, demonstrated 12-month sustained efficacy, and notably lower rates of severe dyspnea compared to other agents 2, 4.
• Lemborexant 5-10 mg: Highly effective for both sleep initiation and maintenance 2, 3, 4. Comparable efficacy to daridorexant but with slightly higher nervous system adverse event signals 2.
• Suvorexant 10-20 mg: Effective but has higher rates of nervous system disorders and daytime drowsiness compared to daridorexant 2, 4.

Key advantages of DORAs:

• No evidence of rebound insomnia or withdrawal 4
• Minimal to no abuse potential 4
• Safe in patients with depression or anxiety 5
• Continued efficacy over long-term use 4

Low-Dose Doxepin (3-6 mg)

Doxepin is an excellent alternative, particularly for pure sleep-maintenance insomnia 6, 2, 5. At low doses (3-6 mg), it selectively blocks histamine H1 receptors without significant anticholinergic effects.

Specific benefits:

• FDA-approved specifically for sleep maintenance 6
• Significantly reduces WASO (SMD = -0.497) 2
• Most prescribed off-label treatment due to efficacy and lack of abuse potential 5
• Well-tolerated in older adults at these low doses 6

Medications to Avoid in This Patient

Why Not Antihistamines

Antihistamines like diphenhydramine (Benadryl) are explicitly not recommended 1. Your patient already experienced sleepwalking—a serious parasomnia indicating paradoxical CNS effects. Guidelines state antihistamines have "lack of demonstrated efficacy as well as safety concerns" 1. Evidence for antihistamines is "generally lacking" except for doxylamine up to 4 weeks 7.

Why Not Melatonin

The patient already failed melatonin. Guidelines confirm "insufficient evidence to determine the efficacy of melatonin in the management of chronic insomnia" 1. While melatonin may have a "time window" of effectiveness (10-40 weeks), this doesn't help your patient who needs immediate relief 2.

Alternative Options (Second-Tier)

Z-Drugs (Nonbenzodiazepine BzRAs)

If DORAs and doxepin are unavailable or contraindicated:

• Zolpidem 10 mg: Effective for sleep maintenance (reduces WASO, SMD = -0.348) but causes daytime drowsiness 6, 2, 3
• Eszopiclone 3 mg: Improves sleep outcomes but lower safety profile than DORAs 6

Critical caveat: Z-drugs should be avoided in older adults due to cognitive impairment, falls, and fractures 6, 5. They're associated with driving impairment and behavioral changes 6.

Benzodiazepines

Not recommended as first-line 1. While effective short-term, they carry risks of dependence, cognitive impairment, falls, and potential association with dementia 6. Reserve for refractory cases only.

Practical Prescribing Algorithm

Step 1: Start daridorexant 25 mg nightly (can increase to 50 mg if needed after 1 week) 4

Step 2: If daridorexant unavailable or not tolerated, use doxepin 3 mg nightly (can increase to 6 mg) 2, 5

Step 3: If both unavailable, consider lemborexant 5 mg (can increase to 10 mg) 2, 4

Step 4: Only if above options fail or are contraindicated, consider zolpidem 10 mg or eszopiclone 3 mg for short-term use (<6 weeks) 5, 8

Essential Non-Pharmacologic Recommendation

Cognitive behavioral therapy for insomnia (CBT-I) should be initiated concurrently 1. This is a strong recommendation based on moderate-quality evidence and provides sustained benefits beyond medication alone 1. Digital CBT-I platforms can address access barriers 5.

Common Pitfalls to Avoid

• Don't use trazodone as first-line: Despite being widely prescribed off-label, guidelines note "insufficient evidence" for trazodone 1
• Don't continue failed medications: Your patient already demonstrated melatonin inefficacy and diphenhydramine intolerance—move on
• Don't prescribe hypnotics indefinitely: Reassess after 4-6 weeks; DORAs are the exception with demonstrated 12-month safety 4
• Don't ignore the sleepwalking: This is a serious adverse event suggesting CNS disinhibition; avoid all sedating antihistamines and use caution with GABAergic agents